WO1999018973A3 - Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte - Google Patents

Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte Download PDF

Info

Publication number
WO1999018973A3
WO1999018973A3 PCT/DE1998/003052 DE9803052W WO9918973A3 WO 1999018973 A3 WO1999018973 A3 WO 1999018973A3 DE 9803052 W DE9803052 W DE 9803052W WO 9918973 A3 WO9918973 A3 WO 9918973A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazaphosphorine
pharmaceutical products
containing pharmaceutical
methanesulfonyloxyethyl
chlorethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1998/003052
Other languages
English (en)
French (fr)
Other versions
WO1999018973A2 (de
Inventor
Matthias Bayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stada Arzneimittel AG
Original Assignee
Stada Arzneimittel AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7845441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999018973(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stada Arzneimittel AG filed Critical Stada Arzneimittel AG
Priority to EP98959738A priority Critical patent/EP1023075B1/de
Priority to AU15550/99A priority patent/AU1555099A/en
Priority to DE19881460T priority patent/DE19881460D2/de
Priority to DE59813853T priority patent/DE59813853D1/de
Publication of WO1999018973A2 publication Critical patent/WO1999018973A2/de
Publication of WO1999018973A3 publication Critical patent/WO1999018973A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es wird eine lagerstabile, gebrauchsfertige Arzneilösung bereitgestellt, umfassend mindestens einen Wirkstoff aus der Gruppe der Oxazaphosphorine der allgemeinen Formel (I), worin R1, R2 und R3 gleich oder verschieden sind und Wasserstoff, Methyl, Ethyl, 2-Chlorethyl oder 2-Methansulfonyloxyethyl bedeuten, mit der Maßgabe, daß R3 nicht Wasserstoff bedeutet, und dabei mindestens zwei dieser Reste 2-Chlorethyl und/oder 2-Methansulfonyloxyethyl sind, eine physiologisch verträgliche, in der wäßrigen Arzneilösung Chloridionen bildende Verbindung sowie gegebenenfalls mindestens einen lösungsvermittelnden Hilfsstoff und/oder mindestens eine Puffersubstanz.
PCT/DE1998/003052 1997-10-13 1998-10-13 Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte Ceased WO1999018973A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98959738A EP1023075B1 (de) 1997-10-13 1998-10-13 Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
AU15550/99A AU1555099A (en) 1997-10-13 1998-10-13 Liquid presentations of oxazaphosphorine-containing pharmaceutical products
DE19881460T DE19881460D2 (de) 1998-10-13 1998-10-13 Flüssige Darreichungsformen oxazaphosphorinhaltiger pharmazeutischer Produkte
DE59813853T DE59813853D1 (de) 1997-10-13 1998-10-13 Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19745246 1997-10-13
DE19745246.9 1997-10-13

Publications (2)

Publication Number Publication Date
WO1999018973A2 WO1999018973A2 (de) 1999-04-22
WO1999018973A3 true WO1999018973A3 (de) 1999-08-26

Family

ID=7845441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/003052 Ceased WO1999018973A2 (de) 1997-10-13 1998-10-13 Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte

Country Status (6)

Country Link
EP (1) EP1023075B1 (de)
AT (1) ATE348621T1 (de)
AU (1) AU1555099A (de)
DE (1) DE59813853D1 (de)
ES (1) ES2277397T3 (de)
WO (1) WO1999018973A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59813853D1 (de) * 1997-10-13 2007-02-01 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
AUPQ849900A0 (en) * 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
AU2002359695A1 (en) * 2001-12-13 2003-06-30 Sicor Inc. Aqueous ifosfamide composition
US7199111B2 (en) 2002-12-02 2007-04-03 Bharat Serums & Vaccines Ltd. Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
DE10346134A1 (de) * 2003-10-01 2005-04-21 Baxter Healthcare Sa Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung
EP1812033A4 (de) * 2004-10-06 2009-11-11 Tiltan Pharma Ltd Verfahren und zusammensetzung zur verstärkung einer anti-angiogenesetherapie
KR20170008252A (ko) * 2014-05-09 2017-01-23 아우로메딕스 파마 엘엘씨 사이클로포스파미드 액상 농축 제제
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254902A2 (de) * 1986-07-11 1988-02-03 ASTA Pharma Aktiengesellschaft Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
EP0538858A1 (de) * 1991-10-23 1993-04-28 Bristol-Myers Squibb Company Verbessertes gefriergetrocknetes Arzneimittel enthaltend Ifosfamid
US5227374A (en) * 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
US5413995A (en) * 1982-11-12 1995-05-09 Mead Johnson & Company Lyophilized cyclophosphamide
WO1999018973A2 (de) * 1997-10-13 1999-04-22 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227374A (en) * 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US5413995A (en) * 1982-11-12 1995-05-09 Mead Johnson & Company Lyophilized cyclophosphamide
EP0254902A2 (de) * 1986-07-11 1988-02-03 ASTA Pharma Aktiengesellschaft Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
EP0538858A1 (de) * 1991-10-23 1993-04-28 Bristol-Myers Squibb Company Verbessertes gefriergetrocknetes Arzneimittel enthaltend Ifosfamid
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
WO1999018973A2 (de) * 1997-10-13 1999-04-22 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOEHRER P J ET AL: "Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide", ANNALS OF INTERNAL MEDICINE, vol. 109, no. 1, 1 October 1988 (1988-10-01), pages 540 - 546, XP002083105 *
MUNOZ M ET AL.: "Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable i.v. pump cassette", AMERICAN JOURNAL OF HOSPITAL PHARMACISTS, vol. 49, 1992, pages 1137 - 71139, XP002103761 *

Also Published As

Publication number Publication date
ES2277397T3 (es) 2007-07-01
EP1023075A1 (de) 2000-08-02
EP1023075B1 (de) 2006-12-20
WO1999018973A2 (de) 1999-04-22
AU1555099A (en) 1999-05-03
ATE348621T1 (de) 2007-01-15
DE59813853D1 (de) 2007-02-01

Similar Documents

Publication Publication Date Title
CA2201749A1 (en) Stable aqueous alfa interferon solution formulations
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
NO994621L (no) Ernaeringsformuleringer inneholdende oligosakkarider
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX9700374A (es) Formulaciones acuosas de risperidona.
CA2282513A1 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
BR9809468A (pt) Formulações farmacêuticas contendo voriconazol
CA2294913A1 (en) Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
CA2317999A1 (en) Pharmaceutical formulation of fluticasone propionate
AU3914097A (en) Preservative systems for pharmaceutical compositions containing cyclodextrins
WO1999018973A3 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
CA2270177A1 (en) Transdermal administration of ment
PL346764A1 (en) New oral formulation for 5-ht4
EP1295879A4 (de) Medizinische zusammensetzungen die propenonderivate enthalten
ATE234868T1 (de) Stabilisator für arzneimittel
NO980058L (no) Opthalmiske preparater
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
ATE181324T1 (de) Im kardiovaskulären system aktive seco-d-steroide und diese enthaltende pharmazeutische zubereitungen
CA2269502A1 (en) Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraetherlipid derivatives, and use thereof
WO2002089770A3 (de) Topische lamellare-doppelmembranstruktur-zusammensetzung, enthaltend n-acyl-ethanolamin und/oder ein quaternäre ammonium salz und/oder adenosylmethionin
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998959738

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998959738

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

REF Corresponds to

Ref document number: 19881460

Country of ref document: DE

Date of ref document: 20010927

WWE Wipo information: entry into national phase

Ref document number: 19881460

Country of ref document: DE

WWG Wipo information: grant in national office

Ref document number: 1998959738

Country of ref document: EP